The researchers at the Medtronic Inc. (MDT) and Eli Lilly & Co. (LLY) said that a new treatment for the Parkinson’s disease will be developed for direct delivery of the medicine in to the brain. The companies announced on Tuesday that they will work on the treatment in collaboration, which may take decades.

The researchers have been facing the challenge from years on how to deliver medicine into the brain, due to the blood-brain barrier. The blood-brain barrier protects the brain from many infections, and it does not let the medicine to enter into the brain.

The Lilly’s drug, glial cell, will preserve the functions of neurons with a system form Medtronic. The Medtronic will help in delivering the medicine into the brain. The protein has already been experimented on the rats.

Stephen Oesterle, Medtronic’s Senior Vice President for Medicine and Technology, said, “We have to deliver it to the right area because proteins can’t cross the blood-brain barrier”.

The companies also said that by working together they will successfully develop a new treatment for Parkinson’s disease.

Globally, Parkinson disease affects almost 7 million to 10 million people and there is no cure for the disease till now.

Meanwhile, it was also revealed that several trials of treatment for the Parkinson disease have been unsuccessful.